Mary Hu received her B.S. degree in Biochemistry from Wuhan University and earned her Ph.D in Molecular Biology from the Institute of Biophysics, Chinese Academy of Sciences in Beijing. After her postdoctoral training at the University of Washington in USA, Dr. Hu moved on to biopharmaceutical industry.
While she worked for the ID Biomedical Corporation and GSK on infectious disease vaccine development, she was responsible for generation of vaccine production clones, potency testing and clinical sample analysis. She later joined Seattle Genetics Inc. for development of cancer therapeutics including monoclonal antibodies and antibody drug conjugates (ADCs). She served as a department head and CMC project lead for bioanalytical testing of non-clinical and clinical sample testing under GLP, bioassay development, process analytics as well as statistical support of CMC process and product development.
Dr. Hu established Shanghai Miracogen Inc. in early 2014.
Minmin Qin received his BS in Plant Genetics and Breeding from Northwest A&F Technology University, and earned his Ph.D. in Genetics / Molecular Biology from University of Wisconsin-Madison.
After his postdoctoral research at UC Berkeley, Dr. Qin joined BioMarin as a founding member with his last position as Senior Director of Process Sciences, overseeing process development, characterization, and validation for all projects including two commercial products. Dr. Qin later joined Five Prime as Senior Director of Process Development, leading all CMC strategies and activities. Dr. Qin returned to China in 2012, and served sequentially as SVP/CTO of Shanghai JMT-Bio and Zhejiang Teruisi, VP of Technology and Process Development of WuXi Biologics, and SVP/ CMC Head of Harbour BioMed. Dr. Qin has many years of experience in successful development and commercialization of biopharmaceuticals and is specialized in various expression technologies as well as process development, process characterization and validation, and GMP manufacturing for antibodies and complex glycoproteins in mammalian systems.
Dr. Qin joined Shanghai Miracogen Inc. in April, 2019 and serves as SVP of CMC.
Maggie Li received her B.S. degree in Chemical Pharmaceutics from Shenyang University of Pharmacy in China and earned her Master degree in Healthcare Administration (MHA) from University of Washington in USA.
Ms. Li has over twenty years’biotechnology and pharmaceutical experience. She worked for Cell Therapeutics Inc., Seattle Genetics Inc. and Acucela Inc. in USA with global regulatory affairs focus and expertise on INDs/CTAs applications and Marketing Applications (NDA/BLA/NDS) as well as Post-Marketing for multiple oncology drugs in different regions including USA, Canada, EU, and China.
Ms. Li joined in Shanghai Miracogen Inc. in early 2014, serves as the Vice President of Regulatory Affairs and is responsible for regulatory strategies and product registration.
Hu Li received his B.S. degree in Chemistry from Nanjing University and earned his M.S. degree in Bioinorganic Chemistry from the Chinese Academy of Sciences in Beijing China. Then he received his Ph.D in Biochemistry from Bryn Mawr College in USA.
Dr. Li worked for GSK for 19 years in drug early development, served as the manager of Platform Technologies and Sciences and project leaders. During his tenure at GSK, he led or participated research or studies of many programs leading to FDA approval. Dr. Li was responsible for target identification and validation, assay development and high throughput screening, mode of action (MOA) studies and preclinical toxicity evaluation of many drug candidates in oncology, immuno-oncology, respiratory and other therapeutic areas.
Dr. Li joined in Shanghai Miracogen Inc. in early 2015, serves as the Vice President of Preclinical Biology.